Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin-induced weight gain.

The primary objective is to compare change in HbA1c on 'triple therapy' (dapagliflozin, semaglutide and insulin) with 'dual therapy' (placebo, semaglutide and insulin).

Who Took Part

The abstract describes 1, participants taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

A sample size recalculation during the trial based on analysis of masked data revised the original recruitment target from 114 to 82 participants.

How the Study Was Run

The design is described as randomized, double-blind, open-label and placebo-controlled.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.

Secondary objectives include comparisons of triple therapy with standard insulin therapy and dual therapy (semaglutide and insulin) with standard insulin therapy.

Safety outcomes include hypoglycaemia and ketosis.

What Was Measured

The subject headings attached to it are Semaglutide, Diabetes Mellitus, Type 1, Glucagon-Like Peptides, Hypoglycemic Agents, Glucosides, Insulin and Benzhydryl Compounds.

The authors tagged it with the keywords adjunct therapy, adjunctive therapy, combination therapy dapagliflozin, ketosis and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Semaglutide in 1, participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 1 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.